Market Comparison Highlights TG Therapeutics' Financial Profile
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
An independent report compared TG Therapeutics to Aurinia Pharmaceuticals across several key business metrics. The comparison covered gross revenue, earnings per share, and valuation. TG Therapeutics reported higher revenue and earnings than Aurinia Pharmaceuticals.
From dailypolitical.com
Why it matters
The analysis detailed specific risk profiles, noting TG Therapeutics has a beta of 1.67, which is higher than Aurinia Pharmaceuticals' beta of 1.4. Institutional ownership of TG Therapeutics stands at 58.6%, compared to 36.8% for Aurinia Pharmaceuticals.
From dailypolitical.com
Who's involved
- TG TherapeuticsMid-cap biopharmaceutical company whose market performance is under review.
Keep exploring
The entities involved
-
TG Therapeutics
a commercial stage biopharmaceutical company
Nothing else this week.